InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives NYSE Noncompliance Notice Over Market Cap and Equity Levels
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on therapies for neurodegenerative diseases, disclosed it received a noncompliance notice from the New York Stock Exchange on March 26, 2025, for falling short of continued listing standards under Section 802.01B. The notice stated that the company’s average global market capitalization over a 30-day period was approximately $37.9 million, while its stockholders’ equity as…